DMR-001 — NDA/BLA submission
H2 2026
We plan to complete additional regulatory submissions for DMR-001 in the second half of 2026 to expand the Phase 1/1b trial globally and enable two proof-of-concept readouts beginning mid-2027.Source filing
DMRA biotech catalysts & pipeline
DAMORA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
DMR-002 — IND submission
H2 2026
As we advance DMR-001, we plan to make our first regulatory submissions for DMR-002 in the second half of 2026 and for DMR-003 in 2027.Source filing
DMR-003 — IND submission
in 2027
As we advance DMR-001, we plan to make our first regulatory submissions for DMR-002 in the second half of 2026 and for DMR-003 in 2027.Source filing
GB3226 (BRM-1420) — Initial data
2027
We would expect initial clinical data for the Phase 1 trial to be available in 2027.Source filing
DMR-001 — Initial data
mid-2027
We expect the readout of two proof-of-concept datasets from this trial beginning mid-2027 and anticipate these data will support our plans for Phase 3 registration-directed trials for DMR-001.Source filing